AREV Life Sciences Global Corp.

CNSX:AREV Stock Report

Market Cap: CA$2.9m

AREV Life Sciences Global Past Earnings Performance

Past criteria checks 0/6

AREV Life Sciences Global has been growing earnings at an average annual rate of 48.7%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 10.2% per year.

Key information

48.7%

Earnings growth rate

51.5%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate10.2%
Return on equityn/a
Net Margin-555.8%
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

Jan 02
How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

Revenue & Expenses Breakdown

How AREV Life Sciences Global makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:AREV Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 220-120
30 Jun 220-120
31 Mar 220-120
31 Dec 210-120
30 Sep 210-210
30 Jun 210-210
31 Mar 210-210
31 Dec 200-110
30 Sep 200-100
30 Jun 200-110
31 Mar 200-220
31 Dec 190-321
30 Sep 190-1021
30 Jun 190-1031
31 Mar 190-911
31 Dec 180-810
30 Sep 180-210
30 Jun 180-110
31 Mar 180-110
31 Dec 170-110
30 Sep 170-110
30 Jun 170000
31 Mar 170000
31 Dec 160000
30 Sep 160000
30 Jun 160000
31 Mar 160000
31 Dec 150000
30 Sep 150000
30 Jun 150000
31 Mar 150000
31 Dec 140000
30 Sep 140000
30 Jun 140000
31 Mar 140000
31 Dec 130000
30 Sep 130000
30 Jun 130000
31 Mar 130000

Quality Earnings: AREV is currently unprofitable.

Growing Profit Margin: AREV is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AREV's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AREV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AREV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).


Return on Equity

High ROE: AREV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/16 16:16
End of Day Share Price 2023/07/20 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AREV Life Sciences Global Corp. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution